MA44021A - Composés antitumoraux - Google Patents

Composés antitumoraux

Info

Publication number
MA44021A
MA44021A MA044021A MA44021A MA44021A MA 44021 A MA44021 A MA 44021A MA 044021 A MA044021 A MA 044021A MA 44021 A MA44021 A MA 44021A MA 44021 A MA44021 A MA 44021A
Authority
MA
Morocco
Prior art keywords
sub
antitumor compounds
antitumor
compounds
cancer
Prior art date
Application number
MA044021A
Other languages
English (en)
Other versions
MA44021B1 (fr
Inventor
Marchante María Del Carmen Cuevas
Solloso Andrés Francesch
Barrasa Valentín Martínez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA44021A publication Critical patent/MA44021A/fr
Publication of MA44021B1 publication Critical patent/MA44021B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

La présente invention concerne un composé de formule générale i, dans laquelle r<sub>1</sub> à r<sub>4</sub> ont diverses significations, et est destiné à être utilisé dans le traitement du cancer.
MA44021A 2017-04-27 2018-04-27 Composés antitumoraux MA44021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (2)

Publication Number Publication Date
MA44021A true MA44021A (fr) 2019-05-15
MA44021B1 MA44021B1 (fr) 2019-08-30

Family

ID=62063080

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Country Status (37)

Country Link
US (4) US10538535B2 (fr)
EP (5) EP3395820B1 (fr)
JP (5) JP6501946B2 (fr)
KR (3) KR102492283B1 (fr)
CN (4) CN110621678A (fr)
AU (4) AU2018260314C1 (fr)
BR (1) BR112019022282A2 (fr)
CA (1) CA3061518A1 (fr)
CL (1) CL2019003057A1 (fr)
CO (1) CO2019011967A2 (fr)
CY (3) CY1121884T1 (fr)
DK (5) DK3395820T3 (fr)
EC (1) ECSP19083967A (fr)
ES (5) ES2960063T3 (fr)
FI (3) FI3615544T3 (fr)
HK (2) HK1255938B (fr)
HR (5) HRP20231233T1 (fr)
HU (5) HUE062032T2 (fr)
IL (3) IL289963B2 (fr)
JO (1) JOP20190254A1 (fr)
LT (5) LT3395821T (fr)
MA (2) MA44021B1 (fr)
MD (5) MD3395820T2 (fr)
ME (2) ME03466B (fr)
MX (3) MX2021016054A (fr)
MY (1) MY198004A (fr)
PH (1) PH12019550224A1 (fr)
PL (5) PL3395820T3 (fr)
PT (2) PT3395821T (fr)
RS (5) RS64686B1 (fr)
SG (2) SG10201913300YA (fr)
SI (5) SI3395820T1 (fr)
TN (2) TN2019000211A1 (fr)
TW (3) TWI742273B (fr)
UY (1) UY37706A (fr)
WO (1) WO2018197663A1 (fr)
ZA (1) ZA201907119B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN115151259A (zh) * 2019-11-21 2022-10-04 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
AU2021260792A1 (en) 2020-04-21 2022-11-24 Pharma Mar, S.A. Drug antibody conjugates
WO2021218896A1 (fr) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 Dérivé de l'ecteinascidine, son procédé de préparation et son utilisation médicale
TW202313039A (zh) 2021-05-19 2023-04-01 西班牙商瑪製藥股份有限公司 Pm14用途與方案

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
EP0048149B1 (fr) 1980-09-12 1983-11-30 University of Illinois Foundation Antibiotiques, dérivés de ceux-ci, procédé de leur extraction et compositions contenant ceux-ci
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH0720966B2 (ja) 1984-12-28 1995-03-08 コンプハルム・エイビ− 製薬学的に活性な化合物を含有する病気治療剤
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
ATE74761T1 (de) 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
ATE69234T1 (de) 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ES2054011T3 (es) 1988-09-05 1994-08-01 Sankyo Co Un proceso para la preparacion de un compuesto, "leualacina".
WO1990005731A1 (fr) 1988-11-24 1990-05-31 University Of Queensland Macromolecules cytotoxiques
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (fr) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
JPH08500112A (ja) 1992-08-12 1996-01-09 ジ・アップジョン・カンパニー タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (fr) 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
EP0973518B1 (fr) 1996-10-24 2006-03-29 The Board Of Trustees Of The University Of Illinois Procedes semi-synthetiques de preparation d'analogues de didemnine
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
ATE421329T1 (de) 1997-05-07 2009-02-15 Pharma Mar Sa Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
EP1067933B1 (fr) 1998-04-06 2007-08-15 The Board Of Trustees Of The University Of Illinois Ecteine-ascidines semi-synthetiques
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
KR100603220B1 (ko) 1998-05-05 2006-07-20 파르마 마르, 에스.에이. 고착성 해양동물의 배양방법
SK285069B6 (sk) 1998-05-11 2006-05-04 Pharma Mar, S. A. Zlúčeniny, ktoré sú metabolitmi ekteinascidínu 743, farmaceutické prostriedky s ich obsahom a ich použitie
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
AU780417B2 (en) 1999-11-15 2005-03-17 Pharma Mar S.A. Aplidine treatment of cancers
WO2001053299A1 (fr) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Composes de la serie saframycine-ecteinascidine, utilisations et synthese
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
CA2400612C (fr) 2000-02-16 2010-05-11 Pharma Mar, S.A. Derives de tetrahydrofuryl oxy- et amino-substitues ayant une activite antitumorale
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ATE339963T1 (de) 2000-04-07 2006-10-15 Univ Pennsylvania Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
CN1436191B (zh) 2000-04-12 2011-09-14 法马马有限公司 抗肿瘤海鞘素衍生物
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
JP2003535868A (ja) 2000-06-06 2003-12-02 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍化合物
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7320981B2 (en) 2000-07-11 2008-01-22 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
US6635054B2 (en) 2000-07-13 2003-10-21 Transurgical, Inc. Thermal treatment methods and apparatus with focused energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
AU2001294024C1 (en) 2000-10-12 2006-11-23 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
HUP0600031A3 (en) 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
CA2428160C (fr) 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions contenant de l'ecteinascidine 743 pour traitement antitumoral
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
EP1353659A1 (fr) 2001-01-24 2003-10-22 Mestex AG Utilisation de substances neurotoxiques pour la production d'un agent servant a traiter les douleurs articulaires
EP1353667A1 (fr) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
EP1360337A1 (fr) 2001-02-09 2003-11-12 The Regents Of The University Of California Composes de la famille de l'ecteinascidine: compositions et procedes
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
CA2462639A1 (fr) 2001-10-19 2003-04-24 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
HUP0401903A3 (en) 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
CA2462642A1 (fr) 2001-10-19 2003-04-24 Pharma Mar, S.A. Utilisation d'aplidine pour le traitement du cancer du pancreas
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
ATE516818T1 (de) 2002-07-31 2011-08-15 Seattle Genetics Inc Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
JP2006501946A (ja) * 2002-10-04 2006-01-19 セント ジュード メディカル エーティージー， インコーポレイテッド 小さい直径の脈管に対して吻合を作製するための自己拡張外部コネクタ、およびその使用方法
WO2004032807A2 (fr) * 2002-10-08 2004-04-22 Sdgi Holdings, Inc. Dispositif et techniques de mise en place d'implants orthopediques
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
EP1572726B1 (fr) 2002-10-18 2010-12-08 Pharma Mar, S.A.U. Composes 4-methylhexanoic kahalalide f
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
WO2004073656A2 (fr) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Conjugues de medicaments anticorps anti-cd70, utilisation desdits conjugues dans le traitement du cancer et des troubles immunitaires
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
UA83022C2 (uk) 2003-03-12 2008-06-10 Фарма Мар, С.А. Аплідин для комбінованої терапії лейкозу та лімфоми
PL1603584T3 (pl) 2003-03-12 2009-02-27 Dana Farber Cancer Inst Inc Aplidyna do leczenia szpiczaka mnogiego
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
CA2528669A1 (fr) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions et methodes de traitement et de diagnostic du cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
JP2006528611A (ja) 2003-07-25 2006-12-21 ノバルティス アクチエンゲゼルシャフト 置換ラクタムおよびそれらの抗がん剤としての使用
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
DE602004018811D1 (de) 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (fr) 2003-11-14 2005-06-02 Pharma Mar, S.A. Therapie anticancer utilisant une combinaison de et-743 et de paclitaxel
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (fr) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
EP1768671A2 (fr) 2004-07-09 2007-04-04 Pharma Mar, S.A. Compositions contenant d'ecteinascidin et undisaccharide pour le traitement du cancer chez les patients ayant un faible niveau de brca1
US20080242670A2 (en) 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
PL1827500T3 (pl) 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
EP1817059A2 (fr) 2004-12-01 2007-08-15 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
WO2006066183A2 (fr) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
CN101171236A (zh) 2005-05-03 2008-04-30 马尔药品公司 抗肿瘤的四氢嘧啶
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
MX2008001585A (es) 2005-08-02 2008-04-22 Pharma Mar Sa Genes involucrados en la biosintesis de tiocoralina y produccion heterologa de la misma.
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
KR101512503B1 (ko) 2006-02-28 2015-04-15 파르마 마르 에스.에이. 개선된 항종양 치료
EP2023931A2 (fr) 2006-05-12 2009-02-18 Pharma Mar S.A. Traitements anticancéreux avec une combinaison de docétaxel et ecteinascidine
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
SG174830A1 (en) 2006-06-16 2011-10-28 Pharma Mar Sa Antitumoral dihydropyran-2-one compounds
WO2009050303A1 (fr) 2007-10-19 2009-04-23 Pharma Mar, S.A. Marqueurs moléculaires pronostiques pour le traitement par et-743
CA2703720A1 (fr) 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Traitements antitumoraux ameliores
WO2009050296A1 (fr) 2007-10-19 2009-04-23 Pharma Mar, S.A. Traitements antitumoraux améliorés
US8748388B2 (en) 2007-12-14 2014-06-10 Pharma Mar, S.A. Antitumoral compounds
EP2597091B1 (fr) 2007-12-20 2016-04-20 Pharma Mar, S.A. Composés antitumoraux
AU2009209541A1 (en) 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
WO2009109649A1 (fr) 2008-03-07 2009-09-11 Pharma Mar, S.A. Traitements anti-tumoraux améliorés
JP2011513429A (ja) 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗癌治療法
CN102065865B (zh) 2008-05-16 2013-03-20 马尔药品公司 多发性骨髓瘤治疗
CN102099025A (zh) 2008-05-16 2011-06-15 马尔药品公司 Pm00104与另一抗肿瘤剂的联合疗法
ES2728163T3 (es) 2008-05-23 2019-10-22 Wyeth Llc Compuestos de triazina como inhibidores de PI3 cinasa y mTOR
EP2321325A1 (fr) 2008-07-03 2011-05-18 Pharma Mar S.A. Macrolides antitumoraux
US8900589B2 (en) 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US20110105409A1 (en) 2008-07-17 2011-05-05 Pharma Mar, S.A. Anticancer Compounds
US20110237520A1 (en) 2008-12-19 2011-09-29 Pharma Mar, Sa Anticancer Compounds
WO2010149688A2 (fr) 2009-06-24 2010-12-29 Pharma Mar, S.A. Composés anticancéreux
UA112746C2 (uk) 2010-04-27 2016-10-25 Фарма Мар, С.А. Протиракові стероїдні лактони, ненасичені в положенні 7(8)
ES2534331T3 (es) 2010-05-25 2015-04-21 Pharma Mar S.A. Proceso sintético para la producción de compuestos e intermedios de ecteinascidina
SI2786753T1 (sl) 2010-11-12 2019-05-31 Pharma Mar S.A. Kombinacijska terapija s protitumorskim antibiotikom
DE102012211024A1 (de) 2012-06-27 2014-01-02 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
SG11201811161YA (en) 2016-07-14 2019-01-30 Pfizer Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
JP2018188432A (ja) 2018-11-29
ES2944344T3 (es) 2023-06-20
PT3395821T (pt) 2019-08-27
JP6501947B2 (ja) 2019-04-17
SI3615544T1 (sl) 2023-07-31
HUE062157T2 (hu) 2023-10-28
HK1255941B (zh) 2020-04-29
EP4101855A1 (fr) 2022-12-14
SI4047002T1 (sl) 2023-07-31
EP3615544A1 (fr) 2020-03-04
RS59173B1 (sr) 2019-10-31
LT3395820T (lt) 2019-08-12
IL295044B2 (en) 2023-11-01
RS64200B1 (sr) 2023-06-30
HUE046109T2 (hu) 2020-02-28
CY1126061T1 (el) 2023-11-15
FI4047002T3 (fi) 2023-05-22
PT3395820T (pt) 2019-08-07
TW201906850A (zh) 2019-02-16
TN2019000211A1 (en) 2021-01-07
DK3395820T3 (da) 2019-08-12
EP4101855B1 (fr) 2023-08-02
IL270153B1 (en) 2023-06-01
ES2741901T3 (es) 2020-02-12
BR112019022282A2 (pt) 2020-05-19
ZA201907119B (en) 2021-07-28
CO2019011967A2 (es) 2020-02-18
US20180312529A1 (en) 2018-11-01
MX2021016054A (es) 2022-06-01
JP7186723B2 (ja) 2022-12-09
ME03466B (fr) 2020-01-20
CN117865987A (zh) 2024-04-12
RS64174B1 (sr) 2023-05-31
LT3615544T (lt) 2023-05-10
SI3395820T1 (sl) 2019-09-30
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
MA44021B1 (fr) 2019-08-30
MA44020A (fr) 2018-10-31
ES2960063T3 (es) 2024-02-29
HK1255938B (zh) 2020-04-29
LT3395821T (lt) 2019-08-12
KR20210126791A (ko) 2021-10-20
AU2022200250B1 (en) 2022-02-10
JP7422812B2 (ja) 2024-01-26
IL270153A (fr) 2019-12-31
CA3061518A1 (fr) 2018-11-01
CN114751920A (zh) 2022-07-15
US20220242883A1 (en) 2022-08-04
EP4101855B9 (fr) 2024-01-03
IL270153B2 (en) 2023-10-01
US11332480B2 (en) 2022-05-17
JP2023052597A (ja) 2023-04-11
EP3395820B1 (fr) 2019-05-15
AU2018260314C1 (en) 2022-04-21
FI3615544T3 (fi) 2023-05-23
ME03467B (fr) 2020-01-20
IL295044B1 (en) 2023-07-01
SG10201913300YA (en) 2020-03-30
DK3395821T3 (da) 2019-08-19
MY198004A (en) 2023-07-25
HRP20191443T1 (hr) 2019-11-15
CY1121884T1 (el) 2020-10-14
JP2018188431A (ja) 2018-11-29
SI3395821T1 (sl) 2019-09-30
RS59174B1 (sr) 2019-10-31
HRP20191442T1 (hr) 2019-11-15
MD3395820T2 (ro) 2019-10-31
KR20220109495A (ko) 2022-08-04
PL3395821T3 (pl) 2019-10-31
MX2021016058A (es) 2022-02-03
WO2018197663A1 (fr) 2018-11-01
IL289963B2 (en) 2023-10-01
DK4047002T3 (da) 2023-05-01
AU2018260314B2 (en) 2021-12-09
US20210070775A1 (en) 2021-03-11
RS64686B1 (sr) 2023-11-30
DK4101855T3 (da) 2023-11-06
HRP20230455T1 (hr) 2023-07-21
TW202344509A (zh) 2023-11-16
KR102492283B1 (ko) 2023-01-27
PL4047002T3 (pl) 2023-07-24
JOP20190254A1 (ar) 2019-10-27
AU2022200250C1 (en) 2022-06-23
CN114736219A (zh) 2022-07-12
LT4101855T (lt) 2023-08-25
JP6501946B2 (ja) 2019-04-17
CN110621678A (zh) 2019-12-27
EP3395821B1 (fr) 2019-05-15
ES2944579T3 (es) 2023-06-22
TW202202509A (zh) 2022-01-16
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
SG11201909841RA (en) 2019-11-28
MD3615544T2 (ro) 2023-08-31
UY37706A (es) 2018-11-30
HRP20230433T1 (hr) 2023-07-07
HRP20231233T1 (hr) 2024-01-19
US10538535B2 (en) 2020-01-21
EP4047002A1 (fr) 2022-08-24
EP4047002B1 (fr) 2023-03-08
CL2019003057A1 (es) 2020-02-21
EP3395820A1 (fr) 2018-10-31
EP3395821A1 (fr) 2018-10-31
SI4101855T1 (sl) 2024-03-29
CY1121885T1 (el) 2020-10-14
US11713325B2 (en) 2023-08-01
AU2022200249C1 (en) 2022-06-23
EP3615544B9 (fr) 2024-01-03
KR20200012846A (ko) 2020-02-05
PL3615544T3 (pl) 2023-07-17
TWI742273B (zh) 2021-10-11
TWI807411B (zh) 2023-07-01
TN2019000210A1 (en) 2021-01-07
LT4047002T (lt) 2023-05-10
ECSP19083967A (es) 2019-12-27
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
PH12019550224A1 (en) 2020-10-12
JP2020517709A (ja) 2020-06-18
DK3615544T3 (da) 2023-05-30
EP3615544B1 (fr) 2023-03-22
IL289963B1 (en) 2023-06-01
IL289963A (en) 2022-03-01
AU2018260314A1 (en) 2019-10-31
IL295044A (en) 2022-09-01
ES2740073T3 (es) 2020-02-05
AU2022200249B1 (en) 2022-02-10
KR102491180B1 (ko) 2023-01-20
FI4101855T3 (fi) 2023-09-22
AU2022201657A1 (en) 2022-03-31
JP2022130682A (ja) 2022-09-06
KR102510975B1 (ko) 2023-03-16
HUE062032T2 (hu) 2023-09-28
MD4047002T2 (ro) 2023-08-31
HUE045641T2 (hu) 2020-01-28
US20210246146A1 (en) 2021-08-12
HUE063736T2 (hu) 2024-01-28
MX2019012812A (es) 2020-01-14

Similar Documents

Publication Publication Date Title
MA44021A (fr) Composés antitumoraux
MA52486B1 (fr) Pyridazinones utilisés en tant qu&#39;inhibiteurs de parp7
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d&#39;une infection par le virus du vih
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA41338B1 (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA42109A (fr) Amides hétérocycliques utilisés en tant qu&#39;inhibiteurs de kinase
MA38454B1 (fr) Inhibiteurs de protéines kinases
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
MA46337B1 (fr) Composé de pyridine
MA27946A1 (fr) Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d&#39;etats pathologiques.
MA38039A1 (fr) Composés de céphem substitués en position 2
MA54386B1 (fr) Modulateurs de trex1
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201791667A1 (ru) Соединения бензоксаборола и их применение
FR3066761B1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
MA39305A3 (fr) Dérivés d&#39;éthynyle
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA48455B1 (fr) Composés antitumoraux
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu&#39;inhibiteur de pde1 humain
MA41885B1 (fr) Mélange d&#39;additifs
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
FR3062796B1 (fr) Utilisation d&#39;un compose appartenant a la famillle des diuretiques pour traiter le cancer
UA114627U (xx) КОМПЛЕКСНА СПОЛУКА НА ОСНОВІ ТЕТРАХЛОРИДУ ОЛОВА ІЗ САЛІЦИЛАЛЬ-n-ТОЛУЇДИНОМ ЯК ПРИСАДКА ДЛЯ ІНГІБУВАННЯ ОКИСНЕННЯ БЕНЗИЛОВОГО СПИРТУ